Home / Pathology / Waiv (RlapsRisk BC, MSIntuit CRC)

Waiv (Paris, FR; spin-off of Owkin)

Waiv (RlapsRisk BC, MSIntuit CRC)

French supplier of AI precision tests for pathology. RlapsRisk BC estimates the recurrence risk in breast cancer from a standard H&E slide; MSIntuit CRC screens colorectal cancer for MSI. Labs use the tests via its own Destra platform or via Sectra, Proscia, Roche and Tribun Health.

Shared spot4of 13 professional tools with a GDPR profileOur summary of what the provider itself publishes about your data: whether the data is stored in the EU (2 points), whether there is a certification or GDPR guarantee (1), and whether the provider is based in the NL or the EU (1). 3 or 4 points is Strong, 2 Good, 1 Limited, 0 Unknown. How we measure in pathology
GDPR: Limited
  • Provider based in the EU

Each tile is a professional tool in pathology, with the strongest GDPR profile on the left. 8 professional tools, like Waiv (RlapsRisk BC, MSIntuit CRC), have a limited GDPR profile: they share this spot. Click for that tool.

Priceon request
Free trialNot foundNot found on the provider's site when checked on 29 October 2026
Based inParis, FR; spin-off from OwkinEU
ModelNot publicProprietary image analysis models on H&E slides (not a language model); RlapsRisk BC and MSIntuit CRC carry CE marking under the IVDR. Which underlying model is used is not public.

Last checked: 29 October 2026 · How we check

Is this your tool? Fill in missing details

What it does

RlapsRisk BC: breast cancer recurrence risk
MSIntuit CRC: MSI screening for colorectal cancer
Works on routine H&E slides
Destra platform for pathologists
Destra API for IMS/LIS
Export results (PDF, CSV, JSON)
BRCAura: gBRCA screening (RUO)
Integration with Sectra, Proscia, Roche, Tribun

Comparable in pathology

All 13 professional tools for pathology
Underlying model

proprietary image analysis models on H&E slides (not a language model); RlapsRisk BC and MSIntuit CRC carry CE marking under the IVDR. Exactly which underlying model is used is not public. Many tools build on a large model from, for example, OpenAI or Anthropic. If in doubt, ask for the data processing agreement: it sets out where your data goes.

GDPR check for pathology

Questions about Waiv (RlapsRisk BC, MSIntuit CRC)

Which AI model does Waiv (RlapsRisk BC, MSIntuit CRC) use?
The maker of Waiv (RlapsRisk BC, MSIntuit CRC) does not publish which AI model sits underneath. Proprietary image analysis models on H&E sections (not a language model); RlapsRisk BC and MSIntuit CRC carry CE marking under the IVDR. Which underlying model is used exactly is not public.
How much does Waiv (RlapsRisk BC, MSIntuit CRC) cost?
on request. Check the current price on the provider's website; rates change often.
Who is Waiv (RlapsRisk BC, MSIntuit CRC) for?
Waiv (RlapsRisk BC, MSIntuit CRC) is aimed at pathology. It fits work such as digitising and managing tissue slides in an image management system (scanners, IMS, archive), detecting and grading cancer on H&E slides (e.g. Gleason score, mitotic count, tumour size), and counting and quantifying biomarkers in IHC staining (HER2, ER/PR, Ki-67, PD-L1).
What should I watch out for with AI in pathology?
You process special category personal data (health) and sometimes data for genetic research. Software for diagnostic use is an in vitro diagnostic medical device: check whether the algorithm is CE-marked under the IVDR for your exact application and tissue type. Many apps are 'research use only'. Choose providers with ISO 27001 and ISO 13485, a data processing agreement and clear data location (EU hosting or on-premise). Also ask whether your slides are used to train models. Under the EU AI Act, medical AI falling under the IVDR is classed as high-risk. Validate every algorithm locally on your own scanner and stains before using it in routine practice.

Every Friday: what changed in AI for pathology

New models, prices, oversight and tools, with sources and what it means for you. One email a week, unsubscribe with one click.

View a sample

We only use your address for this newsletter. You confirm first by email.